{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-25-000223","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2025-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.410190+00:00","generated_at":"2026-05-18T03:27:09.908389+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"BioVie appoints Amy Chappell and Kameel Farag to Board of Directors","bullets":["Board expanded from 4 to 6 members; appointments effective July 17, 2025.","Dr. Chappell: 25 years at Eli Lilly, led CNS drug development including Cymbalta; former CMO of Eliem Therapeutics.","Mr. Farag: former CFO of Aspen Neuroscience (raised $150M+), SVP Finance at Ionis, Regional CFO at Amgen.","BioVie advancing bezisterim Phase 2 trials for early Parkinson's (SUNRISE-PD) and long COVID (ADDRESS-LC)."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-25-000223","json":"https://secwatch.observer/filing/0001520138-25-000223.json","markdown":"https://secwatch.observer/filing/0001520138-25-000223.md","text":"https://secwatch.observer/filing/0001520138-25-000223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013825000223/0001520138-25-000223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013825000223/bivi-20250722_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T03:27:09.908389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}